Full-thickness Rotator Cuff Tear, Rotator Cuff Tendinitis
Conditions
Keywords
Shoulder, Rotator Cuff
Brief summary
The purpose of this study is to compare the functional outcomes of patients with shoulder pathology treated with either ketorolac or corticosteroid injections, in a randomized double-blinded study. Investigators will compare the effectiveness of ketorolac compared to corticosteroid. Specific Aim 1: Hypothesis 1: Injection of the shoulder (in the subacromial space) with Ketorolac will be more effective than corticosteroid injection for the treatment of a variety of shoulder pathologies. The risks associated with this study primarily concern adverse reactions to the study drugs. The drugs used in this study are not narcotics or habit-forming but can have side effects. The patient's physician will screen for any heart, intestinal, or kidney disease or condition that would increase the chance for the patient to have an unwanted side effect.
Detailed description
The proposed study is a three arm, double-blinded, prospective randomized controlled clinical trial with follow-up immediately after the injection and at day 2, and weeks 1, 2, 4, 6, and 12. In this study investigators will compare the effectiveness of ketorolac compared to corticosteroid. Subjects being seen for a rotator cuff injury will be randomized into one of three treatment groups pertaining to their pathology. The intervention will begin once the subject has consented and answered the Baseline Outcome Shoulder Questionnaire. The Baseline Outcome Questionnaire consists of the Visual Analog Score, American Shoulder and Elbow Score, Single Assessment Numeric Evaluation, Pittsburgh Sleep Quality Index, Short Form-12, and questions pertaining to patient characteristics, injury characteristics, co-morbidities, patient history, medications, and demographics.
Interventions
DRUGKetorolac
Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
DRUGMarcaine
Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine
DRUGKenalog
Kenalog: 4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1.
Sponsors
Michael Khazzam
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age: \> or = 18 years old * Rotator Cuff Tendinitis * Atraumatic Full-thickness Rotator Cuff Tear * Subjects who speak English * Women who are of non-childbearing potential
Exclusion criteria
* Age: \< 18 years old * Prior Shoulder Surgery * Fracture * Acute Traumatic Rotator Cuff Tear * Infection * Uncontrolled Diabetes Mellitus (HbA1c \>8) * Uncontrolled High Blood Pressure (Hypertension) * Recent Prior Shoulder Injection in either the Subacromial space Workers Compensation * History of Peptic Ulcer disease (includes both Gastric and Duodenal Ulcers), Gastrointestinal perforation, Inflammatory Bowel disease (Ulcerative Colitis, Crohn's disease), or any other gastrointestinal pathology * Tumor Involving the Shoulder Region * Prior history of gastrointestinal bleeding, allergic reactions, impaired renal function, seizures or cardiac arrhythmias * Subject unable to provide informed consent * Subjects who don't speak English * Patients who are pregnant or lactating at time of screening or are of pregnant bearing age * Patients currently receiving an aspirin, NSAID regimen or any other anti-inflammatory agents that could affect inflammation response. * Patients taking any anti-platelet agents, warfarin or other anticoagulants, or SSRIs. * Patients with any bleeding disorders such as coagulopathy, hypercoagulable state, or platelet disorders including thrombocytopenia. * Patients with cardiac disease such as congestive heart failure, coronary artery disease, or myocardial infarction. * Patients with severe renal failure. Patients with severe liver impairment or active liver disease. * Patients with heavy alcohol use; this is defined as consuming 8 or more drinks per week for a woman and 15 or more drinks per week for a man. * Patients likely to have severe problems maintaining follow-up, including patients diagnosed with severe psychiatric conditions, patients who live too far outside the hospital's catchment area, patients who are incarcerated and patients who have unstable housing situations. Patients with a known hypersensitivity to bupivacaine or other local anesthetic agent of the amide-type. * Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs * Patients who are allergic to aspirin, ketorolac tromethamine and other NSAIDs. * Patients who are currently on probenecid or pentoxifylline as described in the approved label of Ketorolac tromethamine injection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analog Scale | Baseline - pre-injection | Pain as measured by the Visual Analog Scale prior to first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. |
| American Shoulder and Elbow Score (ASES) | Baseline | Pain, instability, and activities of daily living as measured by the American Shoulder and Elbow Score. The ASES is a 100-point scale that consists of two dimensions: pain and activities of daily living. One pain scale is worth 50 points, and activities of daily living worth 50 points. A higher score indicates a better outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Single Assessment Numeric Evaluation (SANE) | Baseline | Measure the patient's self-reported function on a scale of 0 to 100 |
| Pittsburgh Sleep Quality Index (PSQI) | Baseline | Sleep quality as measured by the Pittsburgh Sleep Quality Index |
| Short Form 12 (SF-12) | Baseline | General health survey as measured by the Short Form 12 (SF-12) |
Countries
United States
Outcome results
None listed